Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Sanofi will continue to provide different programs to ensure access and affordability to patients depending on their coverage situations and will continue to monitor policy and market changes. Our ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Biosimilars have been quietly moderating drug prices in the background, Bernstein analyst Ronny Gal said in a recent report. Now, armed with their first biosimilar green light of 2021, Biocon and ...

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...

Californians with diabetes will soon have access to a low-cost insulin pen as part of a new state initiative announced today, October 16, by Gov. Gavin Newsom.Beginning Jan. 1, 2026, CalRx-branded ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...